LDN: Promising Cancer Treatment Evidence

This presentation explores the clinical evidence for Low Dose Naltrexone (LDN) in cancer treatment, drawing from personal experiences with two patients. Both individuals, one with stage 4 melanoma and another with widespread breast cancer metastases, demonstrated unexpected positive responses after taking LDN. The video highlights the potential of LDN to stabilize disease progression and improve patient well-being.

Professor Angus Dalgleish: The clinical evidence with regards to low dose naltrexone was my personal experience of two patients who did not progress as expected. The first one had stage four melanoma and although they had been on a vaccine program, the vaccine program was stopped after 3 months because the manufacturers and the people in charge of the trial decided it was not going to be positive and therefore stopped the study which would normally have required five years of exposure to the vaccine which is really an early form of imunotherapy. This patient had only had 3 months and we had no other alternative. So after several months I became very aware that this patient would have been expected to have progressed in this time and although I had made it clear as with other patients that good vitamin D was really important for the immune system to respond to imunotherapy along with anti-inflammatories and a healthy diet. I still felt she must be taking something I did not know about. And eventually she admitted that she was going to New York to a clinic by Dr. Bahari who was providing her with lowd dose nrexone foot stop. The second patient presented with widespread breast cancer metastasis and was also doing far better than anyone would have predicted with widespread disease involving bone and other areas which would normally be associated with more rapid progression being very slow or stop. I again asked what else she was taking and at this stage she admitted that she also was taking lowd dose nrexone and getting it from the same clinic in New York as the first patient and indeed they knew each other well for stop. I was therefore very impressed that there must be something with this drug or with the drive for these patients to keep accessing various uh agents that might have been prolonging their uh survival. I therefore started to consider giving lowd dose nrexone to patients who had no other options who could no longer take chemotherapy who went on to lowd dose nrexone uh to continue with uh therapy prior to paliotative care and I noted several patients who had liver metastasis could no longer take chemotherapy who went on to lowd dose now trexone continued with static disease over several months. It was interesting that not only did they uh seem to survive longer, but more than one reported that they felt happier since any time of the diagnosis with one of the patients saying that her husband rec regarded them as her happy pills.